Nifedipine and Raynaud's Phenomenon
Authors: ANDRÉ KAHAN
Journal: Annals of Internal Medicine (1981)

Letters and Corrections1 April 1981Nifedipine and Raynaud's PhenomenonANDRÉ KAHAN, M.D., SIMON WEBER, M.D., BERNARD AMOR, M.D., LIONEL SAPORTA, M.D., MAURICE HODARA, M.D., MICHEL DEGEORGES, M.D.ANDRÉ KAHAN, M.D., SIMON WEBER, M.D., BERNARD AMOR, M.D., LIONEL SAPORTA, M.D., MAURICE HODARA, M.D., MICHEL DEGEORGES, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-94-4-546_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: We read with interest the review "Calcium Channel Blocking Agents in the Treatment of Cardiovascular Disorders: Part II: Hemodynamic Effects and Clinical Applications" by Stone and associates (1). We wish to emphasize another indication for use of nifedipine.Numerous therapeutic approaches to Raynaud's phenomenon have been used, with various results (2-5). We have evaluated the therapeutic effect of the calcium-channel blocking agent nifedipine in Raynaud's phenomenon. In each of the 16 patients included in our study (mean age, 38; 12 female, four male) digital vasospasm could be reproduced within 3 minutes by immersion of both hands in...References1. STONEANTMANMULLERBRAUNWALD PEJE. Calcium channel blocking agents in the treatment of cardiovascular disorders: Part II: Hemodynamic effects and clinical applications. Ann Intern Med. 1980;93:886-904. LinkGoogle Scholar2. COFFMAN J. Vasodilator drugs in peripheral vascular disease. N Engl J Med. 1979;300:713-7. CrossrefMedlineGoogle Scholar3. WALDO R. Prazosin relieves Raynaud's vasospasm. JAMA. 1979;241:1037. CrossrefMedlineGoogle Scholar4. POLASAVILAGOZUCCHIATTI PLAV. La vasodilatazione da inibizione di ioni calcio quale fattore di incremento dell'apporto di ossigeno nelle vasculopatie periferiche. Clin Ter. 1977;81:417-31. MedlineGoogle Scholar5. MERIKANGASAUCHENBACH JR. Carbamazepine in Raynaud's disease. Lancet. 1977;2:1186. Letter. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: ANDRÉ KAHAN, M.D.; SIMON WEBER, M.D.; BERNARD AMOR, M.D.; LIONEL SAPORTA, M.D.; MAURICE HODARA, M.D.; MICHEL DEGEORGES, M.D.Affiliations: University René Descartes School of Medicine Paris, France PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited bySpectrophotometric determination of nifedipine in pharmaceutical formulations, serum and urine samples via oxidative coupling reactionCalcium channel blockers for primary Raynaud's phenomenonHistorical Perspective of Raynaud's PhenomenonCase Study: The Determination of a Complex Multi-Systemic Medical Condition by a Cognitive, Virtual Scanning TechniqueCalcium channel blockers for primary Raynaud's phenomenonVibration white fingerThe effects of drugs on wound healing--part II. Specific classes of drugs and their effect on healing woundsRecent developments in the therapy of localized and systemic sclerosisOcclusive arterial disease of the hand due to repetitive blunt trauma: a review with illustrative casesA double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases.Controlled multicenter double-blind trial of nicardipine in the treatment of primary Raynaud phenomenonCalcium-channel blockers and anaesthesiaIndications for Calcium AntagonistsDermatopharmacology: Drugs around the cornerSystemic sclerodermaReferencesIndikationen für Calcium-AntagonistenDigital and radial artery blood flow in patients with Raynaud's phenomenon in response to nifedipineThe bioavailability of oral nifedipine formulations: A statistical and simulation approachScleroderma and scleroderma-like disordersThe treatment of Raynaud's phenomenonPharmacological Treatment of Raynaud's Phenomenon with Special Reference to Calcium-Entry Blockers.Comparison of behavioral treatments for Raynaud's diseaseEffects of Diltiazem on Occupational Raynaud's Syndrome (Vibration Disease)Some Extracardiac Effects of Diltiazem and Other Calcium Entry BlockersEffects of verapamil on calcium-induced rigidity and on filterability of red blood cells from healthy volunteers and patients with progressive systemic sclerosis.The Lack of Effect of Nifedipine on Failing Skin FlapsTreatment of Raynaud's phenomenon with calcium channel blockersVibration syndrome in industry: Dermatological viewpointRaynaud's phenomenon: Pathophysiologic features and treatment with calcium-channel blockersNifedipine in Scleroderma UlcerationsNifedipine-induced fingertip vasodilation in patients with Raynaud's phenomenonDrug Information Analysis ServiceClinical effect of diltiazem acid (Herbesser tablet) for Raynaud phenomenon. A double blind trial comparing with placebo.Possible treatment of pre-eclampsia with calcium channel blocking agentsNifedipine as a therapeutic modality for raynaud's phenomenonRaynaud's SyndromeNewer Therapies for the SclerodermasNifedipine Treatment for Pulmonary Hypertension in a Patient with Systemic SclerosisNifedipine in digital ulceration in sclerodermaNifedipine: Two New UsesNifedipine in the Treatment of Migraine in Patients with Raynaud's PhenomenonLimb ischemia caused by small artery diseaseRaynaud's VasospasmNifedipine Kinetics and Bioavailability After Single Intravenous and Oral Doses in Normal SubjectsNifedipine and a Diabetic UlcerROBERT J. LAZARUS, M.D., ALTUG ONOR, M.D., KHAN HAMEED, M.D.CLINICAL SIGNIFICANCE OF RESISTANT CORYNEBACTERIA GROUP JKEPOPROSTENOL (PROSTACYCLIN) INFUSION IN PATIENTS WITH RAYNAUD'S SYNDROMERaynaud's Disease and NifedipineE. HARRIS PIERCE, M.D., M.S., ROBERT DELLAVALLE, PHARM. D., JAMES WIELENGA, PHARM. D.Therapie der progressiven SklerodermieClinical applications of slow channel blocking compoundsCalcium antagonists: A new class of drugsMicrovascular Reconstruction of the HandCONTROLLED TRIAL OF NIFEDIPINE IN THE TREATMENT OF RAYNAUD'S PHENOMENONInduced Vasodilation as Treatment for Raynaud's DiseaseJARED B. JOBE, Ph.D., JAMES B. SAMPSON, Ph.D., DONALD E. ROBERTS, Ph.D, WILLIAM P. BEETHAM Jr., M.D.Nifedipine in digital ulceration in sclerodermaNifedipine and Alpha-Adrenergic BlockadeDiltiazem and Raynaud's SyndromeMATOBA TSUNETAKA, M.D., MASAHIKO OGATA, M.D., HIROSHI KUWAHARA, M.D.Chapter 9. Antithrombotic AgentsCalcium Channel Blockers and Raynaud's DiseaseMICHEL VAYSSAIRAT, M.D., LOIC CAPRON, M.D., JEAN-NÖEL FIESSINGER, M.D., JEAN-FRANÇOIS MATHIEU, M.D., EDWARD HOUSSET, M.D. 1 April 1981Volume 94, Issue 4_Part_1Page: 546-546KeywordsCalcium channelsCardiovascular therapyHemodynamicsRaynaud syndrome ePublished: 1 December 2008 Issue Published: 1 April 1981 PDF downloadLoading ...